For many years, moderate alcohol intake and its effect on health have been subject to much debate, particularly concerning cardiovascular health. Indeed, light-to-moderate use of alcohol has been ...

(HealthDay News) — Use of a computerized clinical decision support system (CDSS) may reduce the risk of prolonged QT c interval in hospitalized patients at risk for torsades de pointes, according to ...

Tight Glycemic Control of Little Value Post-Pediatric Heart Op Selective serotonin reuptake inhibitors, including citalopram, escitalopram, and amitriptyline, are associated with prolonged corrected ...

Boston, MA - Patients who receive high doses of the antidepressants citalopram or escitalopram could potentially develop QT-interval prolongation, a marker of a slight increased risk for ventricular ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Drugs that prolong the QT interval may increase the risk ...

SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., July 7, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today ...

Tyrosine kinase inhibitors (TKIs) are associated with prolongation of the QTc interval on the electrocardiogram (ECG). The QTc-interval prolongation increases the risk of life-threatening arrhythmias.

Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma Investigation and utilization of molecularly targeted agents has induced a number of drug ...

Please provide your email address to receive an email when new articles are posted on . Compared with married people, unmarried people were more likely to have a prolonged QT interval, according to ...

Results to be Included in BYDUREON™ New Drug Application Resubmission in the Third Quarter of 2011 SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)-- Amylin Pharmaceuticals, Inc. (Nasdaq: ...

Results to be Included in BYDUREON TM New Drug Application Resubmission in the Third Quarter of 2011 SAN DIEGO & INDIANAPOLIS & WALTHAM, Mass.--(BUSINESS WIRE)--Amylin Pharmaceuticals, Inc. (Nasdaq: ...